Bionano Genomics, Inc. (BNGO)

0.9500 +0.0007 (+0.07%) 收市：04:00PM EDT

Bionano Genomics, Inc.

9540 Towne Centre Drive
Suite 100
San Diego, CA 92121
United States
858 888 7600
https://www.bionano.com

版塊: Healthcare
行業: Medical Instruments & Supplies
全職員工: 344

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Robert Erik Holmlin M.B.A., Ph.D.	President, CEO & Director	612.62k	無	1968
Mr. Mark Oldakowski	Chief Operating Officer	472.91k	無	1974
Dr. Alka Chaubey FACMG, Ph.D.	Chief Medical Officer	452.91k	無	1973
Ms. Gulsen Kama M.B.A.	Chief Financial Officer	無	無	1973
Mr. Mark Adamchak CPA	VP of Accounting & Controller	無	無	無
Mr. Jonathan Dixon J.D.	General Counsel & Secretary	無	無	1975
Mr. Stanislas Marin M.B.A., M.S.	Vice President of Global Sales	無	無	無
Ms. Donna Polizio	Global Head of Market Access	無	無	無
Mr. Cory Kreeck	Global Head of People Operations	無	無	無
Dr. Klint Rose Ph.D.	Head of Research & Development	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. The company also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

公司管治

截至 2024年5月1日 止，Bionano Genomics, Inc. 的 ISS 管治質素評分為 10。 Pillar 分數正在審核中：9；董事會：7；股東權利：8；現金賠償：10。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。